Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29754596 | 0.91 | CES2 (0.41) | CES2CES1KDM4E | |
| SCHEMBL28349426 | 0.86 | RIPK1 (0.33) | HDAC1HDAC2HDAC3 | |
| SCHEMBL2468568 | 0.81 | — | — | |
| SCHEMBL13751193 | 0.80 | PIK3CD (0.37) | CES2CES1PIK3CDTSHR | |
| SCHEMBL1127232 | 0.79 | — | — | |
| SCHEMBL4517263 | 0.77 | CES2 (0.38) | CES2CES1PIK3CDHDAC1HDAC2 | |
| Hydrochloric Acid SCHEMBL3991321 | 0.77 | SMN1; SMN2 (0.40) | PIK3CDKDM4EHDAC1HDAC2HDAC3 | |
| Hydrochloric Acid SCHEMBL28315020 | 0.77 | SMN1; SMN2 (0.40) | PIK3CDKDM4EHDAC1HDAC2HDAC3 | |
| SCHEMBL29947305 | 0.76 | CHEK2 (0.32) | PIK3CDKDM4EHDAC1HDAC2HDAC3 | |
| SCHEMBL30636371 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377439-B2 | Heterocyclic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377439-B2 | Heterocyclic prolinamide derivatives | HTRA1, ALDH1A2, HTRA2 | CES2 4790/4885CES1 1812/4885PIK3CD 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.